Free Trial

Erasca (ERAS) Competitors

Erasca logo
$2.38 +0.17 (+7.69%)
Closing price 04:00 PM Eastern
Extended Trading
$2.32 -0.06 (-2.48%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ERAS vs. SRRK, NTLA, HCM, ALVO, BEAM, CDTX, IDYA, RXRX, APGE, and CPRX

Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Scholar Rock (SRRK), Intellia Therapeutics (NTLA), HUTCHMED (HCM), Alvotech (ALVO), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), IDEAYA Biosciences (IDYA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

Erasca vs. Its Competitors

Erasca (NASDAQ:ERAS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Erasca's return on equity of -31.19% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -31.19% -26.34%
Scholar Rock N/A -127.11%-90.09%

67.8% of Erasca shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 14.4% of Erasca shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Erasca has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Erasca currently has a consensus price target of $3.75, indicating a potential upside of 57.56%. Scholar Rock has a consensus price target of $48.50, indicating a potential upside of 63.41%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Scholar Rock
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07

Erasca has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$161.65M-$0.45-5.29
Scholar Rock$33.19M85.96-$246.29M-$2.91-10.20

In the previous week, Scholar Rock had 6 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Scholar Rock and 2 mentions for Erasca. Erasca's average media sentiment score of 0.34 beat Scholar Rock's score of -0.01 indicating that Erasca is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Erasca
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scholar Rock
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Erasca beats Scholar Rock on 8 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERAS vs. The Competition

MetricErascaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$626.91M$3.44B$6.23B$10.68B
Dividend YieldN/A2.26%5.71%4.82%
P/E Ratio-5.2923.9230.0629.84
Price / SalesN/A487.63587.23131.17
Price / CashN/A45.5737.0161.44
Price / Book1.5910.4012.046.60
Net Income-$161.65M-$52.62M$3.32B$276.82M
7 Day Performance-1.65%2.08%1.79%2.07%
1 Month Performance24.61%10.84%6.28%2.62%
1 Year Performance-7.75%13.57%61.13%32.86%

Erasca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERAS
Erasca
2.9325 of 5 stars
$2.38
+7.7%
$3.75
+57.6%
-14.3%$626.91MN/A-5.29120
SRRK
Scholar Rock
4.4391 of 5 stars
$27.92
-0.1%
$48.50
+73.7%
+2.5%$2.69B$33.19M-9.59140
NTLA
Intellia Therapeutics
4.1323 of 5 stars
$27.98
+13.1%
$27.95
-0.1%
+29.8%$2.66B$57.88M-5.97600
HCM
HUTCHMED
2.8005 of 5 stars
$15.10
-0.3%
$20.88
+38.2%
-29.6%$2.64B$630.20M0.001,811
ALVO
Alvotech
3.4135 of 5 stars
$8.59
-1.5%
$14.00
+63.0%
-36.8%$2.63B$560.10M37.351,032Analyst Downgrade
BEAM
Beam Therapeutics
3.7425 of 5 stars
$30.62
+17.9%
$45.92
+50.0%
+29.2%$2.63B$63.52M-6.80510Analyst Forecast
High Trading Volume
CDTX
Cidara Therapeutics
3.9727 of 5 stars
$100.56
-0.9%
$151.33
+50.5%
+751.0%$2.57B$1.27M-9.0490News Coverage
Analyst Forecast
IDYA
IDEAYA Biosciences
4.3273 of 5 stars
$30.51
+4.3%
$44.80
+46.8%
-3.7%$2.56B$7M-8.0580Analyst Forecast
Analyst Revision
RXRX
Recursion Pharmaceuticals
2.0209 of 5 stars
$6.68
+14.0%
$7.25
+8.5%
-9.5%$2.54B$58.84M-3.75400Gap Up
APGE
Apogee Therapeutics
3.1718 of 5 stars
$56.94
+3.2%
$94.00
+65.1%
+4.6%$2.54BN/A-13.7991Analyst Forecast
CPRX
Catalyst Pharmaceuticals
4.8798 of 5 stars
$21.01
+2.2%
$33.20
+58.0%
-2.9%$2.52B$491.73M12.7380Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ERAS) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners